Innogenetics

Value-added diagnostics focusing on infectious diseases, neurodegeneration, and genetic testing; wound care products are developed by a subsidiary of Innogenetics

Innogenetics is a Belgium-based, international biotechnology company involved in diagnostics and therapeutics (“theranostics‿); part of the products are marketed through its wholly-owned subsidiary XCELLentis. XCELLentis, established in February 2001, runs the wound care activities of Innogenetics.

Frank Morich, CEO
Guy Buyens, Chief Therapeutic Officer
Christiaan De Wilde,Chief Financial & Administration Officer

Rudi Mariën, Chairman
Ghislain De Groote, Vice-Chairman
Werner Cautreels
Frank Morich
Luc Geuten
Jos Peeters
Peter Read
Pol Bamelis
Peter Verhaeghe

Technologiepark 6
9052 Gent
Belgium
Phone: +32-9-329-1329
Fax: +32-9-329-1765

The company’s portfolio consists of innovative candidates in the fields of hepatitis C, immune disorders, and wound care (the latter through its wholly owned subsidiary XCELLentis).
The devlopment/product portfolio includes
- new theranostic tests for infectious diseases
- LiPA test for cystic fibrosis
- tests for the early and differential diagnosis of the primary dementias
- autoimmune tests (INNO-LIA ANA Update)
- automated system for simultaneous processing of various tests

XCELLentis has developed two wound care products: LyphoDerm™ is an end-sterilised, freeze-dried lysate derived from cultured allogeneic keratinocytes. Secondly, XCELLentis has invented a biocompatible, hydrogel wound dressing, UlcoDress™ Plus. XCELLentis will apply for CE marking in 2005 to enable commercialisation of its products thoughout Europe.

Innogenetics holds a broad range of patents, a selection of current patents is listed below.

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.